Rifaximin

Drug Profile

Rifaximin

Alternative Names: Dermodis; EIR formulation of rifaximin - Salix Pharmaceuticals; Flonorm; Flonorm®; L 105; Lumenax; Normix; RedActive®; Rifacol; Rifaxidin®; Rifaximin soluble solid dispersion tablet; Rifaximin SSD/next generation formulation; Rifaximin-a 550mg; rifaximin-alpha; Rifaximine®; Spiraxin; Targaxan 550; Tixtar; Xifaxan; Xifaxan 550mg; XIFAXAN550; Xifaxanta; Zaxine

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Alfa Wassermann SpA
  • Developer Alfa Wassermann SpA; ASKA Pharmaceutical; Lupin; Norgine; Salix Pharmaceuticals
  • Class Antibacterials; Antidiarrhoeals; Irritable bowel syndrome therapies; Rifamycins; Small molecules
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatic encephalopathy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diverticulitis; Hepatic encephalopathy; Hyperammonaemia; Intestinal infections; Irritable bowel syndrome; Skin and soft tissue infections; Traveller's diarrhoea
  • Phase III Crohn's disease
  • Phase II Bacterial vaginosis; Liver disorders
  • Discontinued Clostridium infections; Pouchitis; Shigella infections

Most Recent Events

  • 07 Oct 2016 Alfa Wassermann terminates a phase-II clinical trial in Bacterial vaginosis in USA (Vaginal) (NCT02376972)
  • 15 Mar 2016 Biomarkers information updated
  • 10 Mar 2016 Valeant Pharmaceuticals terminates a phase II trial in Hepatic encephalopathy in USA (NCT01846806)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top